Last reviewed · How we verify
transdermal nitroglycerin
At a glance
| Generic name | transdermal nitroglycerin |
|---|---|
| Sponsor | Alison Huang, MD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis (EARLY_PHASE1)
- Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. (NA)
- Topical Nitroglycerine for Prevention of Radial Artery Spasm (PHASE3)
- Flushing Reduction Associated With Nitrates (PHASE2)
- GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy (PHASE2)
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) (PHASE3)
- Nitrate Use to Obtain Radial Spasm Embarrassment (NURSE - TTS Trial) (PHASE3)
- Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- transdermal nitroglycerin CI brief — competitive landscape report
- transdermal nitroglycerin updates RSS · CI watch RSS
- Alison Huang, MD portfolio CI